In vivo RNAi delivery
Monday, 16 February, 2009
Invitrogen has launched its Invivofectamine delivery reagent, which enables siRNA experiments in vivo. As opposed to other offerings on the market, Invivofectamine delivery reagent can be injected in small volumes and without high pressure, minimising the potential of inconsistent results. It also provides extra stability to siRNA so the siRNA will arrive intact and ready to perform the selected knockdown. The reagent is non-viral and has minimal toxicity. Overall, these characteristics will enable researchers to more effectively optimize their siRNA experiments in vivo.
Invitrogen
www.invitrogen.com/invivornai
mRNA therapy found to prevent recurrence of melanoma
Merck and Moderna have announced positive topline results from their Phase 3 trial of a...
A high-performance method for CRISPR off-target nomination
A new study provides evidence that can help gene editing developers prioritise biologically...
High doses of fertility drug linked to pregnancy risks
High doses of clomiphene citrate, accumulated over multiple fertility treatment cycles, could...
